Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00794950 Phase II Sunitinib Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma Completed USA 0
NCT03317158 Phase Ib/II Durvalumab BCG solution + Durvalumab ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder Recruiting USA 0
NCT03672240 Phase Ib/II APL-1202 APL-1202 + BCG solution Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (NMIBC) Completed USA 0
NCT04106115 Phase Ib/II Durvalumab + S-588210 DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE) Recruiting 1
NCT04149574 Phase III BCG solution + Nivolumab BCG solution A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 11
NCT04172675 Phase II Erdafitinib Gemcitabine Mitomycin C A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Recruiting USA | ITA | FRA | ESP | DEU | BEL 11
NCT04640623 Phase II Cetrelimab + TAR-200 TAR-200 A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 10
NCT04752722 Phase Ib/II EG-70 EG-70 in NMIBC Patients Who Are BCG-Unresponsive and High-Risk NMIBC Patients Who Have Been Incompletely Treated With BCG or Are BCG-Naïve (LEGEND STUDY) Recruiting USA 0
NCT04819399 Phase I Catumaxomab Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC Recruiting DEU 0
NCT05259397 Phase I PF-06801591 + PF-07225570 PF-07225570 PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Withdrawn USA 1
NCT05375903 Phase I Imiquimod + Zalifrelimab Zalifrelimab A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Recruiting USA | ESP 0
NCT05483868 Phase I AU-011 A Phase 1, Open-label Trial of AU-011 (Belzupacap Sarotalocan) in NMIBC Recruiting USA 0
NCT05521698 Phase I Apalutamide Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer Not yet recruiting USA 0
NCT05533697 Phase Ib/II mRNA-4359 + Pembrolizumab mRNA-4359 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Recruiting USA 1